-+ 0.00%
-+ 0.00%
-+ 0.00%

Oruka says ORKA-001 hits 71.4% PASI 100 at Week 28 in EVERLAST-A psoriasis trial

PUBT·09/23/2026 11:05:23
Listen to the news
Oruka says ORKA-001 hits 71.4% PASI 100 at Week 28 in EVERLAST-A psoriasis trial
  • Oruka Therapeutics reported positive Week 28 results from its ongoing EVERLAST-A Phase 2a trial of ORKA-001 in plaque psoriasis.
  • Responses continued to deepen months after the last induction dose, supporting a potential infrequent-dosing profile.
  • Patients switching from placebo later in the study showed similar clearance patterns to those treated initially.
  • Safety remained favorable through Week 28, with no new tolerability issues flagged.
  • Week 52 data for all patients are expected in December 2026; initial EVERLAST-B Phase 2b data are due in 4Q 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9831840) on September 23, 2026, and is solely responsible for the information contained therein.